Bringing a gene therapy to market requires more than innovation — it demands a CDMO partner you can trust. In this webinar, discover how our end-to-end viral vector capabilities deliver the expertise, scalability, and reliability needed to advance complex programs with confidence. From process development to GMP manufacturing and regulatory support, learn how our integrated approach helps biotech innovators reduce risk, accelerate timelines, and ensure quality at every step.
In this webinar, you will:
- Explore end-to-end viral vector manufacturing strategies — from process development through GMP production — designed to accelerate timelines without compromising quality
- Understand how robust analytical and regulatory support ensures consistency, compliance, and confidence throughout your gene therapy program
- Learn how strategic CDMO partnerships can de-risk scale-up, streamline tech transfer, and position your therapy for clinical and commercial success
Speaker
Kevin Beck, Ph.D.
MilliporeSigma
Head of Commercial Development
With more than 20 years of expertise in cell and gene therapy, Kevin D. Beck, Ph.D. currently leads the commercial team for the viral vector CDMO business. In this role, he is dedicated to supporting clients in advancing their cell and gene therapies through comprehensive development and manufacturing services. Beck earned his Ph.D. in biological sciences from UC Irvine, and further honed his skills as a post-doctoral fellow at UC San Diego where he researched the mechanisms of differentiation and function of T regulatory cells. His industrial career began with a technical focus on analytics, which seamlessly evolved into commercial roles, emphasizing cell therapy and its transformative potential.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
Duration:1h
Language:English
Session 1:presented June 26, 2025
To continue reading please sign in or create an account.
Don't Have An Account?
